Confined or spread disease-Extends into the skin or chest wall Posts on Medivizor
Navigation Menu

Confined or spread disease-Extends into the skin or chest wall Posts on Medivizor

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...

Read More

Adding ixabepilone to capecitabine treatment for triple negative breast cancer.

Adding ixabepilone to capecitabine treatment for triple negative breast cancer.

Posted by on Dec 11, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if ixabepilone (Ixempra) and capecitabine (Xeloda) work for treating triple-negative breast cancer in patients with hard to treat disease compared to using capecitabine alone. The study found that adding ixabepilone to treatment resulted in longer survival without the cancer progressing. Some background...

Read More

Metronomic chemotherapy for HR+ advanced breast cancer

Metronomic chemotherapy for HR+ advanced breast cancer

Posted by on Nov 7, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well using metronomic chemotherapy with capecitabine (Xeloda) combined with aromatase inhibitors works for patients with hormone receptor positive advanced breast cancer. The study found that this treatment works well and is safe, and therefore should be considered as a potential treatment option. Some...

Read More

Looking for patients with triple negative inoperable breast cancer to test a new treatment option atezolizumab

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) when used with chemotherapy in patients with inoperable, recurrent triple-negative breast cancer. The main outcome to be measured will be the overall survival (time from treatment until death from any cause) of participants.  The...

Read More

Looking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel

Looking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...

Read More

Effects of breast reconstruction compared to mastectomy only on survival and risk of recurrence of breast cancer

Effects of breast reconstruction compared to mastectomy only on survival and risk of recurrence of breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

Layman Title Effects of breast reconstruction compared to mastectomy only on survival and risk of recurrence of breast cancer In a nutshell This study aimed to find out if breast reconstruction using deep inferior epigastric perforator (DIEP) flap reconstruction resulted in higher levels of recurrence compared to mastectomy alone. The authors found that...

Read More

Fulvestrant: an option for estrogen-receptor positive breast cancer that has spread

Fulvestrant: an option for estrogen-receptor positive breast cancer that has spread

Posted by on Aug 5, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare fulvestrant (Faslodex) to other standard endocrine agents in patients with advanced hormone sensitive breast cancer. This study concluded that fulvestrant was as effective as the available standard endocrine agents.  Some background Advanced hormone sensitive breast cancer (BC) is cancer that has...

Read More

The accuracy and relevancy of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer

Posted by on Mar 4, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the accuracy and reliability of sentinel lymph node biopsy (SNLB) before neoadjuvant systemic therapy (NAST) has begun in breast cancer patients. The study concluded that SLNB before NAST is highly reliable. The authors suggested that patients with a negative SLNB may be able to avoid lymph node removal and...

Read More